Non-Nicotine Agents for Smoking Cessation
Status and phase
Completed
Phase 3
Conditions
Tobacco Use Disorder
Treatments
Drug: transdermal patch and nicotine inhaler
Drug: bupropion and transdermal patch
Details and patient eligibility
About
The primary objective of this study is to determine which is the better approach to smoking cessation in veterans: bupropion combined with transdermal nicotine or high dose nicotine replacement therapy (NRT) using transdermal nicotine combined with nicotine inhaler.
Full description
This study is a two-arm open-label, randomized controlled trial of bupropion combined with transdermal nicotine versus high dose NRT (transdermal nicotine and nicotine inhaler) with all subjects receiving a behavioral counseling program for smoking cessation.
Sex
All
Ages
18 to 65 years old
Volunteers
No Healthy Volunteers
Inclusion criteria
- Readiness to set a quit date in the next two weeks,
- Current smoking of at least 15 cigarettes a day
Exclusion criteria
- Current untreated depression or receiving treatment for depression,
- History of seizures, major head injury, or other predisposition for seizures
Trial contacts and locations
1
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal
© Copyright 2026 Veeva Systems